Codexis (CDXS) Competitors $2.81 +0.41 (+17.08%) Closing price 04:00 PM EasternExtended Trading$2.84 +0.03 (+1.07%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDXS vs. RGLS, MYGN, ZBIO, RIGL, EBS, XOMA, CBIO, LXRX, VNDA, and VSTMShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), and Verastem (VSTM). These companies are all part of the "biotechnology" industry. Codexis vs. Its Competitors Regulus Therapeutics Myriad Genetics Zenas BioPharma Rigel Pharmaceuticals Emergent Biosolutions XOMA Royalty Crescent Biopharma Lexicon Pharmaceuticals Vanda Pharmaceuticals Verastem Codexis (NASDAQ:CDXS) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability. Do institutionals & insiders have more ownership in CDXS or RGLS? 78.5% of Codexis shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 2.1% of Codexis shares are held by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, CDXS or RGLS? Regulus Therapeutics has lower revenue, but higher earnings than Codexis. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCodexis$59.35M3.92-$65.28M-$0.99-2.84Regulus TherapeuticsN/AN/A-$46.36M-$0.73-11.18 Does the media refer more to CDXS or RGLS? In the previous week, Regulus Therapeutics had 3 more articles in the media than Codexis. MarketBeat recorded 3 mentions for Regulus Therapeutics and 0 mentions for Codexis. Codexis' average media sentiment score of 1.89 beat Regulus Therapeutics' score of 0.21 indicating that Codexis is being referred to more favorably in the media. Company Overall Sentiment Codexis Very Positive Regulus Therapeutics Neutral Which has more risk and volatility, CDXS or RGLS? Codexis has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Do analysts rate CDXS or RGLS? Codexis currently has a consensus target price of $11.00, suggesting a potential upside of 291.46%. Regulus Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 4.17%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Regulus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Regulus Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29 Is CDXS or RGLS more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Codexis' net margin of -149.47%. Regulus Therapeutics' return on equity of -57.53% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Codexis-149.47% -118.47% -53.37% Regulus Therapeutics N/A -57.53%-53.26% SummaryRegulus Therapeutics beats Codexis on 9 of the 15 factors compared between the two stocks. Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.83M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-2.8421.1726.1419.88Price / Sales3.92278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book3.437.518.055.38Net Income-$65.28M-$55.05M$3.15B$248.50M7 Day Performance11.95%2.45%1.85%2.97%1 Month Performance24.89%7.33%4.81%6.02%1 Year Performance-2.77%5.38%34.86%20.39% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis3.6668 of 5 stars$2.81+17.1%$11.00+291.5%-19.7%$198.83M$59.35M-2.84250Positive NewsGap UpRGLSRegulus Therapeutics1.8926 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830Gap UpMYGNMyriad Genetics4.4521 of 5 stars$5.31+1.1%$14.38+170.9%-76.9%$483.93M$837.60M-4.742,700ZBIOZenas BioPharma1.7823 of 5 stars$9.69+1.1%$36.67+278.4%N/A$400.77M$5M-2.73N/APositive NewsRIGLRigel Pharmaceuticals2.8654 of 5 stars$18.73-3.9%$36.40+94.3%+122.5%$348.15M$179.28M9.05160EBSEmergent Biosolutions4.1986 of 5 stars$6.38+0.5%$14.33+124.7%-6.7%$344.66M$1.04B-2.352,420XOMAXOMA Royalty4.4299 of 5 stars$25.20-8.3%$69.50+175.8%+5.8%$328.97M$28.49M-21.9110High Trading VolumeCBIOCrescent Biopharma3.2795 of 5 stars$16.14+1.5%$25.00+54.9%N/A$310.84M$10K0.0026News CoverageLXRXLexicon Pharmaceuticals2.4617 of 5 stars$0.95+15.2%$3.67+287.7%-47.2%$296.75M$31.08M-1.85140VNDAVanda Pharmaceuticals4.6239 of 5 stars$4.72-1.3%$16.50+249.6%-16.1%$281.71M$198.77M-6.29290VSTMVerastem2.847 of 5 stars$4.15flat$13.38+222.3%+32.0%$228.04M$10K-1.3050 Related Companies and Tools Related Companies RGLS Alternatives MYGN Alternatives ZBIO Alternatives RIGL Alternatives EBS Alternatives XOMA Alternatives CBIO Alternatives LXRX Alternatives VNDA Alternatives VSTM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDXS) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDXS Stock Alerts